A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in Adults

NCT ID: NCT04031040

Last Updated: 2025-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-01

Study Completion Date

2030-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to confirm the safety and clinical effectiveness of the Genio® system in moderate to severe Obstructive Sleep Apnea (OSA) adult patients over a period of 5 years post-surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multicenter, prospective single arm PMCF. Following activation of the Genio® system between 6 to 10 weeks post-surgery, patients will be followed at 3 months, 6 months, 9 months, 12 months and then every year for a total period of 5 years after surgery. Phone calls follow-up will be performed at Month 18, Month 30, Month 42 and Month 54.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genio® system therapy

Following activation of the Genio® system at 8 weeks post-surgery, patients will be followed at 12 weeks, 6 months, 9 months, 12 months and then every year for a total period of 5 years after surgery.

Group Type EXPERIMENTAL

Genio® system therapy

Intervention Type DEVICE

Hypoglossal nerve stimulation system

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genio® system therapy

Hypoglossal nerve stimulation system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body Mass Index (BMI) \< 35 kg/m2
* AHI between 15 to 65 events/hour documented by the closest PSG performed at the time of the patient ICF signature and within maximum 12 months of screening and fulfilling the required technical criteria or during the screening phase.
* Has either not tolerated, has failed or refused Positive Airway Pressure (PAP) or Mandibular Advancement Device (MAD) treatments.

Exclusion Criteria

* Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment;
* Taking medication that in the opinion of the Investigator may alter consciousness, the pattern of respiration, or sleep architecture;
* Major anatomical or functional abnormalities that would impair the ability of the Genio® system to treat OSA;
* Inadequately treated psychiatric disease that prevent patient compliance with the requirements of the investigational study testing;
* Life expectancy \< 12 months;
* Participation in another clinical study (excluding registries) during the study period (3 years).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nyxoah S.A.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joachim T. Maurer, MD

Role: PRINCIPAL_INVESTIGATOR

Klinik für HNO-Heilkunde, Mannheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ziekenhuis Netwerk Antwerpen - ZNA Jan Palfijn

Antwerp, , Belgium

Site Status

Universitair Ziekenhuis Antwerpen

Antwerp, , Belgium

Site Status

CHU - Angers

Angers, , France

Site Status

Centre Hospitalier Intercommunal de Créteil

Créteil, , France

Site Status

Hôpital Henri-Mondor AP-HP

Créteil, , France

Site Status

Hôpital Privé La Louvière

Lille, , France

Site Status

Clinique Beau-Soleil

Montpellier, , France

Site Status

Hôpital Bichat, Assistance Publique - Hôpitaux de Paris

Paris, , France

Site Status

CEREVES Paris Jean Jaurès - Centre du sommeil

Paris, , France

Site Status

Hôpital Tenon AP-HP

Paris, , France

Site Status

CHU - Poitiers

Poitiers, , France

Site Status

Clinique Mutualiste de la Sagesse

Rennes, , France

Site Status

Polyclinique Saint Laurent

Rennes, , France

Site Status

CHU Toulouse

Toulouse, , France

Site Status

Asklepios Klinikum Harburg, Abt. für HNO-Heilkunde, Kopf- und Halschirurgie

Hamburg, , Germany

Site Status

HNO-Klinik des Universitätsklinikums Jena

Jena, , Germany

Site Status

Klinik für HNO-Heilkunde, Kopf- und Halschirurgie, Schlafmedizinisches Zentrum

Mannheim, , Germany

Site Status

Klinikum rechts der Isar der TU München

München, , Germany

Site Status

Helios Universitätsklinikum Wuppertal,Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie

Wuppertal, , Germany

Site Status

Onze Lieve Vrouwe Gasthuis

Amsterdam, , Netherlands

Site Status

Kantonsspital Baselland, Klinik für HNO-Krankheiten, Kopf- und Gesichtschirurgie

Liestal, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium France Germany Netherlands Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CL-GEN-002068

Identifier Type: -

Identifier Source: org_study_id